{"ok":true,"trend":{"id":635973,"platform":"news","region":"global","key":"b7-33 and the expanding frontier of biased ligand research","title":"B7-33 and the Expanding Frontier of Biased Ligand Research","url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOYVRJWW1YM3FtbXlRM2plVVhnVTlJeDZwR1RCbURPVEl2azBtOGtSZjlyYUI2U0M5NXFEcDB4cGZ4WWVSSXdWNzlGUkR6RVpmU1ZNSG9iaG03aDRjRVFzdzg4NHUzSEVDNTdoa3hKTXZoRy1zbW5GT0lHU3QzV3pxNFRtTDRVaGd5UVA0ZzV0N0hMZjVaWE9wOUFQMHpHZDMwTUtTNg?oc=5","first_seen":"2026-10-01T17:48:19.049488Z","last_seen":"2026-10-02T03:27:11.422171Z","last_rank":32,"peak_rank":13,"last_volume":null,"peak_volume":0,"seen_count":8,"score":31.29,"category_hint":"biology","section":"science","category":"biology","summary":"The peptide B7-33, a biased ligand studied for its potential to deliver the therapeutic benefits of the H2 relaxin hormone without unwanted side effects, is drawing attention as research into biased signaling expands. Scientists hope such compounds can activate only beneficial cellular pathways, opening new directions in drug development for fibrosis and cardiovascular conditions.","why":"Growing interest in biased ligands as a promising new approach to safer, more targeted drug design.","tone":"neutral","entities":["B7-33","H2 relaxin"],"summarized_at":"2026-10-01T23:51:22.843054Z","meta":{"via":"scan","lang":"en","term":"biology","source":"Tifton Gazette","published":"Thu, 01 Oct 2026 17:43:19 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"B7-33 and the Expanding Frontier of Biased Ligand Research","section_name":"Science","category_name":"Biology","timeline":[{"captured_at":"2026-10-01T17:48:19.049488Z","rank":14,"volume":null},{"captured_at":"2026-10-01T19:10:41.087819Z","rank":13,"volume":null},{"captured_at":"2026-10-01T20:33:21.362751Z","rank":17,"volume":null},{"captured_at":"2026-10-01T21:55:24.388039Z","rank":21,"volume":null},{"captured_at":"2026-10-01T23:17:23.051275Z","rank":21,"volume":null},{"captured_at":"2026-10-02T00:39:21.063219Z","rank":22,"volume":null},{"captured_at":"2026-10-02T02:01:43.265348Z","rank":31,"volume":null},{"captured_at":"2026-10-02T03:27:11.422171Z","rank":32,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOYVRJWW1YM3FtbXlRM2plVVhnVTlJeDZwR1RCbURPVEl2azBtOGtSZjlyYUI2U0M5NXFEcDB4cGZ4WWVSSXdWNzlGUkR6RVpmU1ZNSG9iaG03aDRjRVFzdzg4NHUzSEVDNTdoa3hKTXZoRy1zbW5GT0lHU3QzV3pxNFRtTDRVaGd5UVA0ZzV0N0hMZjVaWE9wOUFQMHpHZDMwTUtTNg?oc=5","author":"Tifton Gazette","title":"B7-33 and the Expanding Frontier of Biased Ligand Research","snippet":null,"posted_at":"2026-10-01T17:43:19Z","likes":null}],"elsewhere":[],"window":"7d"}}